Visfatin associated with major adverse cardiovascular events in patients with acute myocardial infarction

Abstract

Background Visfatin is an adipokine that related with the inflammation in atherosclerosis and the destabilization of atherosclerotic plaque. The aim of this study was to observe the relationship between visfatin and major adverse cardiovascular events (MACEs) in acute myocardial infarction (AMI) patients. Methods We enrolled a total of 238 patients (183 AMI and 55 control) who underwent coronary angiography. Patients with AMI were followed for an average of 19.3 months and 159 patients were finally included in the study. Results It was observed patients with AMI had higher serum visfatin levels than controls. The total incidence of MACEs was 11.32% (18/159) in AMI patients. After calculation of the Youden index, the best cut-off value of visfatin on the curve of receiver-operating characteristic was 8.799 ng/mL for predicting the occurrence of MACEs. The occurrence of MACEs was elevated in high-visfatin group (≥8.799 ng/mL) compared with low-visfatin group (≤8.799 ng/mL). The time to MACEs was correlated with visfatin (HR = 1.235, 95%CI 1.051–1.451, P = 0.01) and high-visfatin group had an earlier time to MACEs and a shorter time of cumulative survival. Conclusions Increased serum visfatin levels were observed in AMI patients, and correlated with an earlier onset and higher incidence of MACEs.

Sirtuin 1, Visfatin and IL-27 Serum Levels of Type 1 Diabetic Females in Relation to Cardiovascular Parameters and Autoimmune Thyroid Disease

“…Notably, we also found a significant positive correlation between the deceleration time in controls, but not in T1DM women. This finding is consistent with previous studies, suggesting that an increased visfatin plasma level may be involved in the development of HF [90] or adverse CV events [91]. In fact, this adipokine, which is secreted by adipocytes and pro-inflammatory cells [92], probably exerts its effect on CV organs both through paracrine secretion in perivascular [93] and pericardial adipose tissue [94], as well as through its release into the circulation.…”

Relationship between Adipokines and Cardiovascular Ultrasound Parameters in Metabolic-Dysfunction-Associated Fatty Liver Disease

“…Visfatin is a crucial player in promoting atherosclerosis and vascular inflammation. Elevated serum visfatin levels were observed in acute myocardial infarction patients and were linked to the earlier onset and higher incidence of major adverse cardiovascular events (MACE) [ 61 ]. Moreover, serum visfatin levels were positively related to CAD severity in patients with high SYNTAX scores [ 23 ].…”

The relationship of serum visfatin levels with clinical parameters, flow-mediated dilation, and carotid intima-media thickness in patients with ankylosing spondylitis

“…An independent relationship was found between visfatin levels with coronary artery disease and coronary slow-flow phenomenon [25]. Zheng et al found a strong relationship between increased visfatin levels (>8.799 ng/mL) and major adverse cardiovascular events (MACEs) in acute myocardial infarction [26]. Stejskal et al reported that the 20 ng/ mL cut-off value of visfatin is an independent marker for AMI with high sensitivity (84%) and specificity (90%) [27].…”